2-Chlormethyl-1,4,5,6-tetrahydro-pyrimidin | 40403-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Chlormethyl-1,4,5,6-tetrahydro-pyrimidin
• 英文别名: 2-(Chloromethyl)-1,4,5,6-tetrahydropyrimidine
• CAS: 40403-76-7
• 化学式: C₅H₉ClN₂
• mdl: MFCD19218119
• 分子量: 132.593
• InChiKey: MATQOBLZWGLAFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Chlormethyl-1,4,5,6-tetrahydro-pyrimidin 、 [1,1-双环己基]-1-羧酸 在 甲醇 、 异丙醇 、 potassium iodide 作用下， 生成 bicyclohexyl-1-carboxylic acid-(1,4,5,6-tetrahydro-pyrimidin-2-ylmethyl ester); hydrochloride
  参考文献：
  名称：

  Antispasmodics: Esters of Heterocyclic Alcohols

  摘要：

  DOI：

  10.1021/ja01518a051
• 作为产物：
  描述：

  2-Hydroxymethyl-1,4,5,6-tetrahydropyrimidin, Hydrochlorid 在 氯化亚砜 作用下， 生成 2-Chlormethyl-1,4,5,6-tetrahydro-pyrimidin
  参考文献：
  名称：

  Antispasmodics: Esters of Heterocyclic Alcohols

  摘要：

  DOI：

  10.1021/ja01518a051

文献信息

• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。
• [EN] BETA CARBOLINES AND USES THEREOF<br/>[FR] BÊTA-CARBOLINES ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2009067233A1

  公开（公告）日：2009-05-28

  This invention provides beta-carboline compounds of formula I: wherein R1, R2, R3, R4, R5, G, and x are as described in the specification. The compounds are useful for treating cancer and inflammatory disorders.

  本发明提供了公式I的β-咔啉化合物：其中R1、R2、R3、R4、R5、G和x如说明书所述。这些化合物可用于治疗癌症和炎症性疾病。
• 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
  申请人：Hutchinson John H.

  公开号：US20090221574A1

  公开（公告）日：2009-09-03

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了包含这些化合物的药物组合物，这些化合物调节5-脂氧合酶活化蛋白（FLAP）的活性。本文还描述了使用这样的FLAP调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或病症。
• Alpha carbolines and uses thereof
  申请人：Hepperle E. Michael

  公开号：US20070207997A1

  公开（公告）日：2007-09-06

  This invention provides alpha-carboline compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and x are as described in the specification. The compounds are useful for treating inflammatory diseases and cancer.

  本发明提供了式I的α-咔唑啉化合物：其中R1、R2、R3、R4、R5和x如说明书中所述。该化合物对于治疗炎症性疾病和癌症具有用处。
• 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Panmira Pharmaceuticals, LLC

  公开号：US20140018394A1

  公开（公告）日：2014-01-16

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和含有这些化合物的药物组合物，可调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这种FLAP调节剂的方法，单独或与其他化合物组合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的疾病或病情。